CD79a moleculeGenealiases: IGA · IGAlpha · MB-1 · MB1
Q-omics provides the consensus-scored CD79A profile across patient tissues and cancer cell-line models. CD79A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CD79A is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, CD79A RNA expression shows 16,844 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where CD79A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD79A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD79A survival associations across molecular data types. CD79A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD79A RNA expression–survival associations across cancer types. High CD79A expression shows favorable associations in HNSC, SKCM, LUAD, BRCA, UCEC and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CD79A RNA expression.
This table summarizes CD79A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CD79A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD79A shows lower tumor expression in COAD, READ and LIHC and higher tumor expression in LUAD and KIRC. The COAD box plot shows higher CD79A RNA expression in normal versus tumor tissue (log2 FC = −3.692, t-test p < 0.001).
This table shows molecular features associated with CD79A in patient tissues and cancer cell lines. In patient samples, CD79A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CD79A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Lymphoma.
